Perdicaro, Julin Gambarte Tudela, Victoria Muscia, Ariel R
2010 Jun;13(3):135-43
A cadmium protein from equine kidney cortex
Examples: 5 mg, 10 mg, 15 mg, 20 mg, or another vial strength
Common Types of Modifications Fatty acid conjugation Used to extend half-life by enhancing albumin binding (common in long-acting GLP-1 analogs) Oxidation (e.g., Methionine oxidation) Can occur during manufacturing or storage, affecting stability Deamidation (Asparagine, Glutamine) Leads to structural changes that may alter biological activity Truncation or cleavage products Results from degradation, impacting peptide integrity Why Detecting Modifications Matters Affects bioavailability and efficacy Structural changes can alter receptor binding and therapeutic performance Critical for regulatory submissions Regulatory agencies require detailed characterization of all variants and impurities Ensures product stability Helps monitor degradation pathways during stability studies Supports biosimilarity assessments Essential for comparing innovator and generic GLP-1 products 8: Data Analysis and Interpretation Accurate data analysis and interpretation are essential in Peptide Sequencing of GLP-1 Peptide to ensure correct sequence assignment, reliable impurity identification, and confident characterization of structural modifications
$95 B12 1,000mcg Single Injection
